US FDA’s Prasad: ‘We Will Always Embrace Surrogate Endpoints’

 
• By Sarah Karlin-Smith
  
Vinay Prasad
CBER Director Vinay Prasad discussed accelerated approval and cancer with FDA Commissioner Martin Makary after a 20 May presentation. (US FDA webstream)

More from US FDA

More from R&D